The ascendancy of second-generation antipsychotics as frontline antimanic agents

Journal of Clinical Psychopharmacology

Volumn 35, Issue 6, 2015, Pages 645-653

  Miller, Christopher J ^a,b   Li, Mingfei ^c,d   Penfold, Robert B ^e,f   Lee, Austin F ^c,d,g,h   Smith, Eric G ^c,i   Nordberg, Samuel S ^a   Osser, David N ^c   Bajor, Laura ^a   Zhang, Fang ^j   Bauer, Mark S ^a,b  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BENTLEY UNIVERSITY   (United States)

^e GROUP HEALTH RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g XI'AN UNIVERSITY OF FINANCE AND ECONOMICS   (China)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^j HARVARD PILGRIM HEALTH CARE   (United States)

more..

Author keywords

antipsychotic; atypical; bipolar; second generation; Veteran

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; QUETIAPINE; RISPERIDONE; SECOND GENERATION ANTIPSYCHOTIC; UNCLASSIFIED DRUG; VALPROIC ACID; ZIPRASIDONE; TRANQUILIZER;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; BORDERLINE STATE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; EVIDENCE BASED PRACTICE; EXPERIMENTAL THERAPY; FEMALE; HEART ARRHYTHMIA; HUMAN; HYPERLIPIDEMIA; ICD-9; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; OBESITY; PATIENT DECISION MAKING; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RACE DIFFERENCE; SLEEP DISORDER; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; TRAUMATIC BRAIN INJURY; AGED; GOVERNMENT; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; AGED; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 84947026706     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000405     Document Type: Article

References (74)

1. Mathews SC, Pronovost PJ. Physician autonomy and informed decision making: finding the balance for patient safety and quality. JAMA. 2008;300:2913-2915.
2. Panzano PC, Roth D. The decision to adopt evidence-based and other innovative mental health practices: risky business? Psychiatr Serv. 2006;57: 1153-1161.
3. Brook RH. Can the Patient-Centered Outcomes Research Institute become relevant to controlling medical costs and improving value? JAMA. 2011; 306:2020-2021.
4. Kuehn BM. Questionable antipsychotic prescribing remains common, despite serious risks. JAMA. 2010;303:1582-1584.
5. Law MR, Ross-Degnan D, Soumerai SB. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatr Serv. 2008;59:540-546.
6. Bauer MS, Lee A, Li M, et al. Off-label use of second generation antipsychotics for post-traumatic stress disorder in the Department of Veterans Affairs: time trends and sociodemographic, comorbidity, and regional correlates. Pharmacoepidemiol Drug Saf. 2014;23:77-86.
7. Rogers EM. Diffusion of Innovations. New York: Simon and Schuster; 2010.
8. Mitchell PB, Hadzi-Pavlovic D. Lithium treatment for bipolar disorder. Bull World Health Organ. 2000;78:515-517.
9. Andlin-Sobocki P, Wittchen HU. Cost of affective disorders in Europe. Eur J Neurol. 2005;12(suppl 1):34-38.
10. Baldessarini RJ, Tondo L. Suicide risk and treatments for patients with bipolar disorder. JAMA. 2003;290:1517-1519.
11. Peele PB, Xu Y, Kupfer DJ. Insurance expenditures on bipolar disorder: clinical and parity implications. Am J Psychiatry. 2003;160:1286-1290.
12. McElroy SL, Keck PE Jr, Pope HG Jr, et al. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J Clin Psychopharmacol. 1992;12(suppl 1):42S-52S.
13. Hirschfeld RM, Kasper S. A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder. Int J Neuropsychopharmacol. 2004;7:507-522.
14. Healy D. The latest mania: selling bipolar disorder. PLoS Med. 2006; 3:e185.
15. Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007;64:442-455.
16. Cruz N, Sanchez-Moreno J, Torres F, et al. Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. Int J Neuropsychopharmacol. 2010;13:5-14.
17. De Fruyt J, Deschepper E, Audenaert K, et al. Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. J Psychopharmacol. 2012;26:603-617.
18. Smith LA, Cornelius V, Warnock A, et al. Effectiveness ofmood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord. 2007; 9:394-412.
19. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159: (suppl 4):1-50.
20. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2013. Bipolar Disord. 2013;15:1-44.
21. VA/DoD. Management of Bipolar Disorder in Adults (BD). Washington, DC: Department of Veterans Affairs and Department of Defense; 2010.
22. National Institute for Health and Clinical Excellence: Guidance. Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents, in Primary and Secondary Care. London: National Institute for Health and Clinical Excellence; 2006.
23. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31-41.
24. Reist C, Mintz J, Albers LJ, et al. Second-generation antipsychotic exposure and metabolic-related disorders in patients with schizophrenia: an observational pharmacoepidemiology study from 1988 to 2002. J Clin Psychopharmacol. 2007;27:46-51.
25. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1): 1-93.
26. Guo JJ, Keck PE Jr, Corey-Lisle PK, et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study. J Clin Psychiatry. 2006;67:1055-1061.
27. Friedman RA. A call for caution on antipsychotic drugs. New York Times. September 24, 2012: D6.
28. Sernyak M, Rosenheck R. Experience of VA psychiatrists with pharmaceutical detailing of antipsychotic medications. Psychiatr Serv. 2007;58:1292-1296.
29. Spielmans GI. The promotion of olanzapine in primary care: an examination of internal industry documents. Soc Sci Med. 2009;69:14-20.
30. Herbeck DM, West JC, Ruditis I, et al. Variations in use of second-generation antipsychotic medication by race among adult psychiatric patients. Psychiatr Serv. 2004;55:677-684.
31. Copeland LA, Zeber JE, Valenstein M, et al. Racial disparity in the use of atypical antipsychotic medications among veterans. Am J Psychiatry. 2003;160:1817-1822.
32. Opolka JL, Rascati KL, Brown CM, et al. Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine. Psychiatr Serv. 2004; 55:151-156.
33. Valenstein M, McCarthy JF, Ignacio RV, et al. Patient-and facility-level factors associated with diffusion of a new antipsychotic in the VA health system. Psychiatr Serv. 2006;57:70-76.
34. Wang PS, West JC, Tanielian T, et al. Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull. 2000;26:451-457.
35. YangM, Barner JC, LawsonKA, et al. Antipsychoticmedication utilization trends among Texas veterans: 1997-2002. Ann Pharmacother. 2008;42: 1229-1238.
36. Kreyenbuhl J, Zito JM, Buchanan RW, et al. Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull. 2003;29: 183-193.
37. Kuno E, Rothbard AB. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry. 2002;159: 567-572.
38. Owen RR, FengW, Thrush CR, et al. Variations in prescribing practices for novel antipsychotic medications among Veterans Affairs hospitals. Psychiatr Serv. 2001;52:1523-1525.
39. Mark TL, Dirani R, Slade E, et al. Access to new medications to treat schizophrenia. J Behav Health Serv Res. 2002;29:15-29.
40. GarverD, Lazarus A, RajagopalanK, et al. Racial differences inmedication switching and concomitant prescriptions in the treatment of bipolar disorder. Psychiatr Serv. 2006;57:666-672.
41. Kilbourne AM, Pincus HA. Patterns of psychotropic medication use by race among veterans with bipolar disorder. Psychiatr Serv. 2006;57: 123-126.
42. Daumit GL, Crum RM, Guallar E, et al. Outpatient prescriptions for atypical antipsychotics for African Americans, Hispanics, and whites in the United States. Arch Gen Psychiatry. 2003;60:121-128.
43. Connolly A, Taylor D, Sparshatt A, et al. Antipsychotic prescribing in Black and White hospitalised patients. J Psychopharmacol. 2011;25: 704-709.
44. Connolly A, Taylor D. Ethnicity and quality of antipsychotic prescribing among in-patients in south London. Br J Psychiatry. 2008;193:161-162.
45. Bauer MS, Lee A, Miller CJ, et al. Effects of diagnostic inclusion criteria on prevalence and population characteristics in database research. Psychiatr Serv. 2015;66:141-148.
46. Gören JL, Meterko M, Williams S, et al. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Psychiatr Serv. 2013;64:527-533.
47. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithiummaintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64:1013-1024.
48. Hirschowitz J, Kolevzon A, Garakani A. The pharmacological treatment of bipolar disorder: the question of modern advances. Harv Rev Psychiatry. 2010;18:266-278.
49. Carta MG, HardoyMC, Hardoy MJ, et al. The clinical use of gabapentin in bipolar spectrum disorders. J Affect Disord. 2003;75:83-91.
50. Miller CJ, Li M, Penfold RB, et al. Patterns of initiation of second generation antipsychotics for bipolar disorder: a month-by-month analysis of provider behavior. BMC Psychiatry. 2014;14:339.
51. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61:123-136.
52. Wine JN, Sanda C, Caballero J. Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions. Ann Pharmacother. 2009;43: 707-713.
53. Gedge L, Lazowski L, Murray D, et al. Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression. Neuropsychiatr Dis Treat. 2010;6:501-508.
54. Gao K, Ganocy SJ, Gajwani P, et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry. 2008;69:302-309.
55. Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. CNS Drug Rev. 2007;13:137-177.
56. Li AP. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact. 2002;142: 7-23.
57. Vestergaard P. Clinically important side effects of long-term lithium treatment: a review. Acta Psychiatr Scand Suppl. 1983;305:1-36.
58. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Waltham, MA: Academic Press; 2013.
59. Chen H, Cohen P, Chen S. How big is a big odds ratio? Interpreting the magnitudes of odds ratios in epidemiological studies. Communications in Statistics-Simulation and Computation®. 2010;39:860-864.
60. Bagalman E. The Number of Veterans That Use VA Health Care Services: A Fact Sheet. Washington, DC: Congressional Research Service; 2014.
61. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170:1249-1262.
62. Matza LS, Rajagopalan KS, Thompson CL, et al. Misdiagnosed patients with bipolar disorder: comorbidities, treatment patterns, and direct treatment costs. J Clin Psychiatry. 2005;66:1432-1440.
63. Arnold LM, Keck PE Jr, Collins J, et al. Ethnicity and first-rank symptoms in patients with psychosis. Schizophr Res. 2004;67:207-212.
64. Tsai AC, Rosenlicht NZ, Jureidini JN, et al. Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. PLoS Med. 2011; 8:e1000434.
65. Lin EH, Katon WJ, Simon GE, et al. Achieving guidelines for the treatment of depression in primary care: is physician education enough? Med Care. 1997;35:831-842.
66. Goncalves DA, Fortes S, Campos M, et al. Evaluation of a mental health training intervention for multidisciplinary teams in primary care in Brazil: a pre-and posttest study. Gen Hosp Psychiatry. 2013;35:304-308.
67. Steinman MA, Landefeld CS, Gonzales R. Predictors of broad-spectrum antibiotic prescribing for acute respiratory tract infections in adult primary care. JAMA. 2003;289:719-725.
68. Garrison GD, Levin GM. Factors affecting prescribing of the newer antidepressants. Ann Pharmacother. 2000;34:10-14.
69. Penfold RB, Wang W, Pajer K, et al. Spatio-temporal clusters of new psychotropic medications among Michigan children insured by Medicaid. Pharmacoepidemiol Drug Saf. 2009;18:531-539.
70. Penfold RB, Kelleher KJ. Use of surveillance data in developing geographic dissemination strategies: a study of the diffusion of olanzapine to Michigan children insured by medicaid. Clin Ther. 2007;29:359-370.
71. Simon SR, Rodriguez HP, Majumdar SR, et al. Economic analysis of a randomized trial of academic detailing interventions to improve use of antihypertensive medications. J Clin Hypertens (Greenwich). 2007;9: 15-20.
72. Swann AC, Bowden CL, Calabrese JR, et al. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology. 2002;26:530-536.
73. Bowden CL, Collins MA, McElroy SL, et al. Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo. Neuropsychopharmacology. 2005;30:1932-1939.
74. PanahiazarM, Taslimitehrani V, Jadhav A, et al. Empowering Personalized Medicine With Big Data and Semantic Web Technology: Promises, Challenges, and Use Cases. Washington DC: IEEE International Conference on Big Data; 2014.